
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3582276/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of a TNFR2-Selective Agonistic TNF-α Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander. Journal of Immunology, 2021, 206, 1740-1751.	0.4	12
2	COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	26
3	Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics. Journal of Biological Chemistry, 2020, 295, 9379-9391.	1.6	7
4	Search for drug discovery targets focusing on cancer stroma. Translational and Regulatory Sciences, 2019, 1, 58-65.	0.2	0
5	A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification. Journal of Biological Chemistry, 2017, 292, 6438-6451.	1.6	14
6	Modifying the Surface of Silica Nanoparticles with Amino or Carboxyl Groups Decreases Their Cytotoxicity to Parenchymal Hepatocytes. Biological and Pharmaceutical Bulletin, 2017, 40, 726-728.	0.6	7
7	Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique. Biochemistry and Biophysics Reports, 2016, 7, 309-315.	0.7	7
8	A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLoS ONE, 2015, 10, e0144712.	1.1	39
9	Protein corona changes mediated by surface modification of amorphous silica nanoparticles suppress acute toxicity and activation of intrinsic coagulation cascade in mice. Nanotechnology, 2015, 26, 245101.	1.3	47
10	Identification and evaluation of metastasis-related proteins, oxysterol binding protein-like 5 and calumenin, in lung tumors. International Journal of Oncology, 2015, 47, 195-205.	1.4	50
11	Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3. Biochemical and Biophysical Research Communications, 2015, 456, 908-912.	1.0	16
12	Aminopeptidase P3 (APP3), a novel member of the TNF/TNFR2 signaling complex, induces phosphorylation of JNK. Journal of Cell Science, 2015, 128, 656-69.	1.2	18
13	Cutaneous exposure to agglomerates of silica nanoparticles and allergen results in IgE-biased immune response and increased sensitivity to anaphylaxis in mice. Particle and Fibre Toxicology, 2015, 12, 16.	2.8	22
14	Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro. Nanoscale Research Letters, 2014, 9, 651.	3.1	14
15	Intestinal absorption and biological effects of orally administered amorphous silica particles. Nanoscale Research Letters, 2014, 9, 532.	3.1	49
16	Evaluation of silica nanoparticle binding to major human blood proteins. Nanoscale Research Letters, 2014, 9, 2493.	3.1	24
17	Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. Journal of Controlled Release, 2014, 189, 72-79.	4.8	44
18	Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochemical and Biophysical Research Communications, 2014, 450, 545-549.	1.0	27

#	Article	IF	CITATIONS
19	Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. Particle and Fibre Toxicology, 2013, 10, 41.	2.8	61
20	Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference in gel electrophoresis. Neuroscience Letters, 2013, 534, 85-89.	1.0	38
21	Liver-specific microRNAs as biomarkers of nanomaterial-induced liver damage. Nanotechnology, 2013, 24, 405102.	1.3	49
22	Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Medicine, 2013, 2, 972-977.	1.3	34
23	Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology, 2012, 23, 045101.	1.3	62
24	Distribution and histologic effects of intravenously administered amorphous nanosilica particles in the testes of mice. Biochemical and Biophysical Research Communications, 2012, 420, 297-301.	1.0	68
25	Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochemical and Biophysical Research Communications, 2012, 421, 140-144.	1.0	25
26	Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles. Nanoscale Research Letters, 2012, 7, 555.	3.1	15
27	Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells. Biochemical and Biophysical Research Communications, 2012, 427, 553-556.	1.0	40
28	Surface modification of amorphous nanosilica particles suppresses nanosilica-induced cytotoxicity, ROS generation, and DNA damage in various mammalian cells. Biochemical and Biophysical Research Communications, 2012, 427, 748-752.	1.0	51
29	Novel TNF-α Receptor 1 Antagonist Treatment Attenuates Arterial Inflammation and Intimal Hyperplasia in Mice. Journal of Atherosclerosis and Thrombosis, 2012, 19, 36-46.	0.9	29
30	Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection. Particle and Fibre Toxicology, 2012, 9, 3.	2.8	75
31	Limited expression of reticulocalbin-1 in lymphatic endothelial cells in lung tumor but not in normal lung. Biochemical and Biophysical Research Communications, 2011, 405, 610-614.	1.0	8
32	Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. Nature Nanotechnology, 2011, 6, 321-328.	15.6	622
33	Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. Journal of Controlled Release, 2011, 149, 8-14.	4.8	49
34	Effect of amorphous silica nanoparticles on in vitro RANKL-induced osteoclast differentiation in murine macrophages. Nanoscale Research Letters, 2011, 6, 464.	3.1	19
35	Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. Biomaterials, 2011, 32, 3-9.	5.7	54
36	Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Biomaterials, 2011, 32, 162-169.	5.7	31

#	Article	IF	CITATIONS
37	Promotion of allergic immune responses by intranasally-administrated nanosilica particles in mice. Nanoscale Research Letters, 2011, 6, 195.	3.1	50
38	Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages. Nanoscale Research Letters, 2011, 6, 93.	3.1	71
39	Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. Particle and Fibre Toxicology, 2011, 8, 1.	2.8	229
40	Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. Biomaterials, 2011, 32, 2713-2724.	5.7	161
41	Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning. Biomaterials, 2011, 32, 5498-5504.	5.7	15
42	Identification of New Candidates as Mucosal Vaccine Adjuvant in TNF Family Cytokines. Advances in Experimental Medicine and Biology, 2011, 691, 299-304.	0.8	1
43	Anti-inflammatory Effects of a Novel TNFR1-Selective Antagonistic TNF Mutant on Established Murine Collagen-Induced Arthritis. Advances in Experimental Medicine and Biology, 2011, 691, 493-500.	0.8	5
44	An in vitro method for screening anti-platelet agents using a microchannel array flow analyzer. Biorheology, 2010, 47, 153-161.	1.2	5
45	In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood, 2010, 115, 736-744.	0.6	60
46	Urban Aerosols Induce Pro-inflammatory Cytokine Production in Macrophages and Cause Airway Inflammation in Vivo. Biological and Pharmaceutical Bulletin, 2010, 33, 780-783.	0.6	14
47	Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza Virus. Journal of Virology, 2010, 84, 12703-12712.	1.5	109
48	Carbon Nanotubes Elicit DNA Damage and Inflammatory Response Relative to Their Size and Shape. Inflammation, 2010, 33, 276-280.	1.7	143
49	Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2. Cytokine, 2010, 50, 75-83.	1.4	5
50	Potential adjuvant effect of intranasal urban aerosols in mice through induction of dendritic cell maturation. Toxicology Letters, 2010, 199, 383-388.	0.4	10
51	The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses. Biomaterials, 2009, 30, 5869-5876.	5.7	33
52	Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery. Proteomics, 2009, 9, 783-787.	1.3	9
53	Crystallization and preliminary X-ray analysis of the tumour necrosis factor α–tumour necrosis factor receptor type 2 complex. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 295-298.	0.7	10
54	The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains. Biomaterials, 2009, 30, 3318-3323.	5.7	9

#	Article	IF	CITATIONS
55	The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials, 2009, 30, 6638-6647.	5.7	50
56	Creation of a mutant IFN-Î $\pm 8$ with enhanced anti-HCV activity using the phage display technique. Cytokine, 2009, 48, 58.	1.4	0
57	TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochemical and Biophysical Research Communications, 2009, 384, 296-300.	1.0	16
58	Novel protein engineering strategy for creating highly receptor-selective mutant TNFs. Biochemical and Biophysical Research Communications, 2009, 388, 667-671.	1.0	7
59	Structure–Function Relationship of Tumor Necrosis Factor (TNF) and Its Receptor Interaction Based on 3D Structural Analysis of a Fully Active TNFR1-Selective TNF Mutant. Journal of Molecular Biology, 2009, 385, 1221-1229.	2.0	65
60	Fast Binding Kinetics and Conserved 3D Structure Underlie the Antagonistic Activity of Mutant TNF: Useful Information for Designing Artificial Proteo-Antagonists. Journal of Biochemistry, 2009, 146, 167-172.	0.9	15
61	Arsenic Trioxide Inhibits Human T Cell-Lymphotropic Virus-1-Induced Syncytiums by Down-Regulating gp46. Biological and Pharmaceutical Bulletin, 2009, 32, 1286-1288.	0.6	2
62	Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. Journal of Immunological Methods, 2008, 335, 71-78.	0.6	11
63	Organelle-Targeted Delivery of Biological Macromolecules Using the Protein Transduction Domain: Potential Applications for Peptide Aptamer Delivery into the Nucleus. Journal of Molecular Biology, 2008, 380, 777-782.	2.0	24
64	The therapeutic effect of TNFR1-selective antagonistic mutant TNF-α in murine hepatitis models. Cytokine, 2008, 44, 229-233.	1.4	47
65	Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist. Journal of Biological Chemistry, 2008, 283, 998-1007.	1.6	89
66	Creation of Novel Cell-Penetrating Peptides for Intracellular Drug Delivery Using Systematic Phage Display Technology Originated from Tat Transduction Domain. Biological and Pharmaceutical Bulletin, 2007, 30, 218-223.	0.6	32
67	Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochemical and Biophysical Research Communications, 2007, 363, 1027-1032.	1.0	45
68	Protein C inhibitor inhibits breast cancer cell growth, metastasis and angiogenesis independently of its protease inhibitory activity. International Journal of Cancer, 2007, 121, 955-965.	2.3	43
69	Role of amino acid residue 90 in bioactivity and receptor binding capacity of tumor necrosis factor mutants. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2007, 1774, 1029-1035.	1.1	7
70	A novel method for construction of gene fragment library to searching epitopes. Biochemical and Biophysical Research Communications, 2006, 346, 198-204.	1.0	6
71	Quality Enhancement of the Non-immune Phage scFv Library to Isolate Effective Antibodies. Biological and Pharmaceutical Bulletin, 2006, 29, 1325-1330.	0.6	25
72	Creation of Novel Protein Transduction Domain (PTD) Mutants by a Phage Display-Based High-Throughput Screening System. Biological and Pharmaceutical Bulletin, 2006, 29, 1570-1574.	0.6	25

#	Article	IF	CITATIONS
73	Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 251-258.	0.9	8
74	Functionalization of Tumor Necrosis Factor-α Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window. Clinical Cancer Research, 2004, 10, 8293-8300.	3.2	76
75	Design of a pH-Sensitive Polymeric Carrier for Drug Release and Its Application in Cancer Therapy. Clinical Cancer Research, 2004, 10, 2545-2550.	3.2	64
76	Poly(vinylpyrrolidone-co-dimethyl maleic acid) as a novel renal targeting carrier. Journal of Controlled Release, 2004, 95, 229-237.	4.8	39
77	Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma. International Journal of Cancer, 2004, 108, 516-523.	2.3	41
78	Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen. Journal of Biomedical Materials Research Part B, 2004, 70A, 219-223.	3.0	12
79	The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials, 2004, 25, 3259-3266.	5.7	175
80	The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials, 2004, 25, 4309-4315.	5.7	58
81	Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen. Biochemical and Biophysical Research Communications, 2004, 323, 583-591.	1.0	31
82	In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer. Thrombosis Research, 2004, 114, 195-203.	0.8	28
83	Protective role of activated protein C in lung and airway remodeling. Critical Care Medicine, 2004, 32, S262-S265.	0.4	38
84	Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood, 2004, 103, 2196-2204.	0.6	91
85	Selective Enhancer of Tumor Vascular Permeability for Optimization of Cancer Chemotherapy. Biological and Pharmaceutical Bulletin, 2004, 27, 437-439.	0.6	5
86	Synthesis of a poly(vinylpyrrolidone-coÂ-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nature Biotechnology, 2003, 21, 399-404.	9.4	114
87	Incorporation of adult organ-derived endothelial cells into tumor blood vessel. Biochemical and Biophysical Research Communications, 2003, 306, 219-224.	1.0	18
88	Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice. Journal of Controlled Release, 2000, 68, 335-341.	4.8	29
89	In Vitro Remodeling of Tumor Vascular Endothelial Cells Using Conditioned Medium from Various Tumor Cells and Their Sensitivity to TNF-α. Biochemical and Biophysical Research Communications, 2000, 268, 809-813.	1.0	16
90	Molecular Design of Conjugated Tumor Necrosis Factor-α: Synthesis and Characteristics of Polyvinyl Pyrrolidone Modified Tumor Necrosis Factor-α. Biochemical and Biophysical Research Communications, 1999, 257, 448-453.	1.0	34

#	Article	IF	CITATIONS
91	Bioconjugation of Laminin-Related Peptide YIGSR with Polyvinyl Pyrrolidone Increases Its Antimetastatic Effect Due to a Longer Plasma Half-Life. Biochemical and Biophysical Research Communications, 1999, 264, 763-767.	1.0	19
92	PEGylation of Interleukin-6 Effectively Increases Its Thrombopoietic Potency. Thrombosis and Haemostasis, 1997, 77, 168-173.	1.8	34